在1型人类免疫缺陷病毒感染个体中，与完整的原始分离病毒粒子发生反应的血清抗体发生率极低。
Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.
作者信息
Cavacini L A, Peterson J E, Nappi E, Duval M, Goldstein R, Mayer K, Posner M R
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
J Virol. 1999 Nov;73(11):9638-41. doi: 10.1128/JVI.73.11.9638-9641.1999.
Abstract
Immunoglobulin G reactive with primary isolate virions was detected in 36% of serum samples from individuals infected with human immunodeficiency virus type 1. Of these individuals, serum samples from only 7% captured significant quantities of virus. Virion-specific antibody correlated with CD4 counts and, of more significance, primary isolate neutralization. Further dissection of this response should lead to the identification of antibodies and antigenic epitopes for vaccine purposes.
摘要
在感染1型人类免疫缺陷病毒的个体的36%血清样本中检测到与原始分离毒株病毒体反应的免疫球蛋白G。在这些个体中，只有7%的血清样本捕获了大量病毒。病毒体特异性抗体与CD4细胞计数相关，更重要的是，与原始分离毒株中和作用相关。对这种反应的进一步剖析应该会有助于鉴定用于疫苗目的的抗体和抗原表位。
相似文献
1
Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.
J Virol. 1999 Nov;73(11):9638-41. doi: 10.1128/JVI.73.11.9638-9641.1999.
2
Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.
J Virol. 2003 Nov;77(21):11385-97. doi: 10.1128/jvi.77.21.11385-11397.2003.
3
Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
AIDS Res Hum Retroviruses. 2003 Jul;19(7):597-607. doi: 10.1089/088922203322230969.
4
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
J Virol. 2000 Aug;74(15):7096-107. doi: 10.1128/jvi.74.15.7096-7107.2000.
5
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
J Virol. 2000 Jun;74(12):5403-11. doi: 10.1128/jvi.74.12.5403-5411.2000.
6
Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions.
AIDS. 2002 Dec 6;16(18):2409-17. doi: 10.1097/00002030-200212060-00005.
7
Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
J Med Virol. 2003 Feb;69(2):173-81. doi: 10.1002/jmv.10288.
8
Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
J Gen Virol. 2017 Jul;98(7):1879-1891. doi: 10.1099/jgv.0.000824. Epub 2017 Jul 12.
9
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.
J Virol. 2011 Nov;85(21):11196-207. doi: 10.1128/JVI.05601-11. Epub 2011 Aug 24.
10
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Science. 2013 May 10;340(6133):751-6. doi: 10.1126/science.1233989.
引用本文的文献
1
Novel monoclonal antibodies to the SERINC5 HIV-1 restriction factor detect endogenous andvirion-associated SERINC5.
MAbs. 2020 Jan-Dec;12(1):1802187. doi: 10.1080/19420862.2020.1802187.
2
SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
J Virol. 2020 Sep 29;94(20). doi: 10.1128/JVI.00594-20.
3
Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.
J Immunol Res. 2016;2016:9425172. doi: 10.1155/2016/9425172. Epub 2016 Jun 22.
4
Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.
Immun Inflamm Dis. 2015 Jun;3(2):82-93. doi: 10.1002/iid3.52. Epub 2015 Mar 11.
5
Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.
J Virol. 2013 Aug;87(16):9233-49. doi: 10.1128/JVI.01145-13. Epub 2013 Jun 5.
6
Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.
J Immunol. 2013 Jan 1;190(1):205-10. doi: 10.4049/jimmunol.1201469. Epub 2012 Nov 26.
7
A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.
J Virol. 2008 May;82(9):4671-4. doi: 10.1128/JVI.02499-07. Epub 2008 Feb 13.
8
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.
Virology. 2008 Mar 1;372(1):187-200. doi: 10.1016/j.virol.2007.10.018. Epub 2007 Nov 26.
9
Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
J Virol. 2006 Sep;80(17):8745-62. doi: 10.1128/JVI.00956-06.
10
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
J Virol. 2004 Mar;78(5):2394-404. doi: 10.1128/jvi.78.5.2394-2404.2004.
本文引用的文献
1
Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80. doi: 10.1089/aid.1998.14.1271.
2
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59. doi: 10.1038/31405.
3
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
Science. 1998 Jun 19;280(5371):1949-53. doi: 10.1126/science.280.5371.1949.
4
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
AIDS Res Hum Retroviruses. 1998 May 1;14(7):591-7. doi: 10.1089/aid.1998.14.591.
5
Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
AIDS Res Hum Retroviruses. 1998 May 1;14(7):545-50. doi: 10.1089/aid.1998.14.545.
6
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
J Virol. 1998 Jun;72(6):4694-703. doi: 10.1128/JVI.72.6.4694-4703.1998.
7
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.
Immunol Lett. 1997 Jun 1;57(1-3):105-12. doi: 10.1016/s0165-2478(97)00043-6.
8
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions.
J Virol. 1997 May;71(5):3444-50. doi: 10.1128/JVI.71.5.3444-3450.1997.
9
Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.
J Virol. 1997 Mar;71(3):2512-7. doi: 10.1128/JVI.71.3.2512-2517.1997.
10
Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
Virology. 1996 Apr 1;218(1):258-63. doi: 10.1006/viro.1996.0188.
Zotero 插件